By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein
If your pipeline contains a compound with significant activity against COVID-19, you have a duty to investigate it for that purpose, at the least. Many companies — arguably, too many — are thus engaged these days. But there is another way to approach the challenge: Find the molecule and found a company to develop it.